Skip to main content
. 2016 Jul 11;21(6):1191–1195. doi: 10.1007/s10147-016-1019-4

Fig. 1.

Fig. 1

Changes in the creatinine clearance ratio in patients treated by zoledronic acid followed by denosumab therapy. Renal function of all patients who changed from zoledronic acid to denosumab for any cause (a). Renal function of patients who changed from zoledronic acid to denosumab due to deterioration of renal function (b). ZOL zoledronic acid, DEN denosumab, *statistically significant difference between values (p < 0.001)